These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19924443)

  • 1. Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.
    Andrew AS; Gui J; Hu T; Wyszynski A; Marsit CJ; Kelsey KT; Schned AR; Tanyos SA; Pendleton EM; Ekstrom RM; Li Z; Zens MS; Borsuk M; Moore JH; Karagas MR
    BJU Int; 2015 Feb; 115(2):238-47. PubMed ID: 24666523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer.
    Lipunova N; Wesselius A; Cheng KK; van Schooten FJ; Cazier JB; Bryan RT; Zeegers MP
    Biomark Cancer; 2019; 11():1179299X19897255. PubMed ID: 31908559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer.
    Ceylan C; Yahşi S; Doğan S; ÖztÜrk E; Ceylan G
    Ir J Med Sci; 2018 Nov; 187(4):1115-1119. PubMed ID: 29453645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic Studies.
    Zhang N; Jiang G; Liu X; Na R; Wang X; Xu J
    Biomed Res Int; 2016; 2016():9859021. PubMed ID: 27896277
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses.
    Sankhwar M; Sankhwar SN; Bansal SK; Gupta G; Rajender S
    Sci Rep; 2016 Jun; 6():27018. PubMed ID: 27246180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPC codon 939 polymorphism is associated with susceptibility to DNA damage induced by aflatoxin B1 exposure.
    Long XD; Huang HD; Huang XY; Yao JG; Xia Q
    Int J Clin Exp Med; 2015; 8(1):1197-204. PubMed ID: 25785113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of DNA repair gene polymorphisms and aflatoxin B1 in the risk of hepatocellular carcinoma.
    Yao JG; Huang XY; Long XD
    Int J Clin Exp Pathol; 2014; 7(9):6231-44. PubMed ID: 25337275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.
    Dai QS; Hua RX; Zeng RF; Long JT; Peng ZW
    Tumour Biol; 2014 Jan; 35(1):447-53. PubMed ID: 23918308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.
    Zhang Y; Wang X; Zhang W; Gong S
    Tumour Biol; 2013 Apr; 34(2):973-82. PubMed ID: 23269608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between polymorphisms of DNA repair genes significantly modulated bladder cancer risk.
    Zhi Y; Yu J; Liu Y; Wei Q; Yuan F; Zhou X; Song B; Chen Z; Yang J
    Int J Med Sci; 2012; 9(6):498-505. PubMed ID: 22927776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?
    Lima L; Dinis-Ribeiro M; Longatto-Filho A; Santos L
    Adv Urol; 2012; 2012():232609. PubMed ID: 22919375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk.
    Liu Y; Wang H; Lin T; Wei Q; Zhi Y; Yuan F; Song B; Yang J; Chen Z
    Oncol Rep; 2012 Jul; 28(1):337-45. PubMed ID: 22505326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
    Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
    Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
    Yang X; Liu D; Wu H; Kang H; Pang H; Huang D; Sha X; Wang E; Wang Z; Wei M
    Cancer Sci; 2012 Jul; 103(7):1207-14. PubMed ID: 22519360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.
    Dou K; Xu Q; Han X
    Diagn Pathol; 2013 Jul; 8():112. PubMed ID: 23819639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between XPC polymorphisms and risk of cancers: A meta-analysis.
    Qiu L; Wang Z; Shi X; Wang Z
    Eur J Cancer; 2008 Oct; 44(15):2241-53. PubMed ID: 18771913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.
    Gangwar R; Mandhani A; Mittal RD
    J Cancer Res Clin Oncol; 2010 May; 136(5):779-86. PubMed ID: 19924443
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.